莎普爱思(603168.SH)子公司获得盐酸毛果芸香碱滴眼液临床试验批准通知书

Core Viewpoint - The company, ShaPu AiSi (603168.SH), has received approval from the National Medical Products Administration for clinical trials of a new eye drop product aimed at treating presbyopia in adults [1] Group 1: Company Developments - ShaPu AiSi's wholly-owned subsidiary, Zhejiang ShaPu Health Management Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" for the drug, which is identified as hydrochloride pilocarpine eye drops [1] - The company plans to initiate clinical trials once conditions are met [1] - As of the announcement date, the total research and development investment for the hydrochloride pilocarpine eye drops project has reached approximately 6.4457 million RMB [1]